A compound of formula: in which each of A 1, A 2, A 3, A 4, A 5, and A 6, independently, is methylene; B 1 is a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, or a bivalent heteroaryl radical; B 2 is a bond, a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, D 1 -NR 1 -C -D 2, D 1 -C NR 1 -D 2 -NR 1 '-C -D 3, D 1 -D 2 -C -NR 1 -C -D 3, or D 1 -D 2 -D 3, each of D 1, D 2, D 3, independently, being a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, a C 1 -C 10 bivalent aralkyl radical, or a C 1 -C 10 bivalent heteroaralkyl radical, and each of R 1 and R 1 ', independently, being H, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, or a C 1 -C 10 bivalent aralkyl radical; L 1 is a bond, NR 2, NR 2 C, NR 2 C, NR 2 CR 3 R 4, NR 2 SO 2, NR 2 C NR 3, or NR 2 C NR 3, each of R 2, R 3, and R 4, independently, being H, a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, a C 1 -C 14 monovalent heteroaralkyl radical, C(s)R', or C R', in which R' is a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, or a C 1 -C 14 monovalent heteroaralkyl radical; L 2 is C; each of W 1, W 2, W 3, W 4, W 5, W 6, W 7, and W 8, independently, is N or CH; X is a bond, O, S, or NR 6, R 6 being H, a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, or a C 1 -C 14 monovalent heteroaralkyl radical; Y is a aryl ring or a heteroaryl ring selected from the group consisting of and Z is an anticancer therapeutic moiety selected from the group consisting of wherein each of the aliphatic radical, the heteroaliphatic radical, the aralkyl radical, and the heteroaralkyl radical is unsubstituted or substituted with halo, cyano, amino, hydroxyl, nitro, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 12 dialkylamino, and C 1 -C 6 haloalkyl; and each of the aryl radical and the heteroaryl radical is unsubstituted or substituted with halo, cyano, amino, hydroxyl, nitro, sulfhydryl, a C 1 -C 6 aliphatic radical, a C 1 -C 6 heteroaliphatic radical, or a haloaliphatic radical. each of A 1, A 2, A 3, A 4, A 5, and A 6, independently, is methylene; B 1 is a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, or a bivalent heteroaryl radical; B 2 is a bond, a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, D 1 -NR 1 -C -D 2, D 1 -C NR 1 -D 2 -NR 1 '-C -D 3, D 1 -D 2 -C -NR 1 -C -D 3, or D 1 -D 2 -D 3, each of D 1, D 2, D 3, independently, being a C 1 -C 6 bivalent aliphatic radical, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, a C 1 -C 10 bivalent aralkyl radical, or a C 1 -C 10 bivalent heteroaralkyl radical, and each of R 1 and R 1 ', independently, being H, a C 1 -C 6 bivalent heteroaliphatic radical, a bivalent aryl radical, a bivalent heteroaryl radical, or a C 1 -C 10 bivalent aralkyl radical; L 1 is a bond, NR 2, NR 2 C, NR 2 C, NR 2 CR 3 R 4, NR 2 SO 2, NR 2 C NR 3, or NR 2 C NR 3, each of R 2, R 3, and R 4, independently, being H, a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, a C 1 -C 14 monovalent heteroaralkyl radical, C(s)R', or C R', in which R' is a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, or a C 1 -C 14 monovalent heteroaralkyl radical; L 2 is C; each of W 1, W 2, W 3, W 4, W 5, W 6, W 7, and W 8, independently, is N or CH; X is a bond, O, S, or NR 6, R 6 being H, a C 1 -C 6 monovalent aliphatic radical, a C 1 -C 6 monovalent heteroaliphatic radical, a monovalent aryl radical, a monovalent heteroaryl radical, a C 1 -C 14 monovalent aralkyl radical, or a C 1 -C 14 monovalent heteroaralkyl radical; Y is a aryl ring or a heteroaryl ring selected from the group consisting of and Z is an anticancer therapeutic moiety selected from the group consisting of wherein each of the aliphatic radical, the heteroaliphatic radical, the aralkyl radical, and the heteroaralkyl radical is unsubstituted or substituted with halo, cyano, amino, hydroxyl, nitro, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 12 dialkylamino, and C 1 -C 6 haloalkyl; and each of the aryl radical and the heteroaryl radical is unsubstituted or substituted with halo, cyano, amino, hydroxyl, nitro, sulfhydryl, a C 1 -C 6 aliphatic radical, a C 1 -C 6 heteroaliphatic radical, or a haloaliphatic radical.